National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Guselkumab (Tremfya®) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.


NCPE Assessment Process Complete
Rapid review commissioned 01/12/2017
Rapid review completed 06/02/2018
Rapid Review outcome Full pharmacoeconomic assessment recommended at the submitted price


The HSE has approved reimbursement following confidential price negotiations: April 2018